Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia

British Journal of Clinical Pharmacology

Volumn 80, Issue 5, 2015, Pages 1001-1009

  Assouline, Sarit ^a   Buccheri, Valeria ^b   Delmer, Alain ^c   Gaidano, Gianluca ^d   McIntyre, Christine ^e   Brewster, Michael ^e   Catalani, Olivier ^f   Hourcade Potelleret, Florence ^f   Sayyed, Pakeeza ^f   Badoux, Xavier ^g  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c SERVICE DE DERMATOLOGIE   (France)

^d UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g ST GEORGE HOSPITAL   (Australia)

Author keywords

chronic lymphocytic leukaemia; cyclophosphamide; fludarabine; pharmacokinetics; rituximab; subcutaneous

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; ANTINEOPLASTIC AGENT; VIDARABINE;

ADULT; AGED; AREA UNDER THE CURVE RATIO; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHOLECYSTITIS; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PATIENT PREFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PATIENT PREFERENCE; RITUXIMAB; VIDARABINE;

EID: 84946489900     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12662     Document Type: Article

References (20)

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S,. International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-74.
2. Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, Lõpez-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L,. PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013; 14: 962-70.
3. Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H,. German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009; 27: 3994-4001.
4. Frost GI,. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007; 4: 427-40.
5. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI,. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114: 230-41.
6. Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J,. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage 2009; 38: 663-72.
7. Harb G, Lebel F, Battikha J, Thackara JW,. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin 2010; 26: 279-88.
8. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C,. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 2012; 13: 869-78.
9. Keating M, O'Brien S,. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 2000; 27: 86-90.
10. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ,. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-70.
11. Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, Schmidt J,. Development of a subcutaneous formulation for trastuzumab-nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Drug Res 2012; 62: 401-9.
12. Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, Schmidt J,. Development of a subcutaneous formulation for trastuzumab-nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Drug Res 2013; 63: 602.
13. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner N,. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2013; 53: 192-201.
14. Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G,. A comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase Ib study. J Clin Oncol 2014; 32: 1782-91.
15. Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, Berge C, Bittner B, Boehnke A, McIntyre C, Macdonald D,. Pharmacokinetics, safety, and efficacy of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol 2014; 15: 343-52.
16. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ,. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-56.
17. Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, Mangat R, Joshi A, Visich J,. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol 2012; 52: 1918-26.
18. Beal S, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM User's Guides (1989-2011). Ellicott City: Icon Development Solutions, 2011.
19. Wang DD, Zhang S, Zhao H, Men AY, Parivar K,. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49: 1012-24.
20. Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A,. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-73.